Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
This is not because the technology is "too new" or "awaiting approval." It is because no product has demonstrated the safety and efficacy required for approval through the rigorous clinical trial process that real medications undergo
plantarum probiotic separately
Market cap gains far exceed historical trends: In an equivalent time period prior to the launch of their GLP-1 products, the combined market cap gains for Novo Nordisk and Eli Lilly was significantly lower at $197 billion3.5x less than the gains realized after the introduction of these products
Morgan GLP-1 supply is expected to increase across the globe GLP-1 penetration remains low globally, with roughly 7% of diabetes patients and 2% of the obese population currently using these medications
The incidence of type 2 diabetes has also been rising throughout the world in the past decades, with this trend of increase stabilizing and even reversing in some populations only in the last 20 years (Magliano et al., 2019)
Eli Lilly Files the Paperwork (Late 2026) After the trials finish, Eli Lilly puts together a massive application (called a New Drug Application, or NDA) that includes all the safety and effectiveness data
US$ 26.24
US$ 28.90
US$ 20.33
US$ 22.34
US$ 26.70
US$ 21.45
